BridgeBio Pharma (BBIO) wins FDA nod Attruby for rare heart disorder, ATTR-CM challenging Pfizer's (PFE) Vyndaqel. Read more ...
The approval of Attruby for transthyretin amyloidosis with cardiomyopathy begins a battle for control of a lucrative market ...
Ultromics Ltd. received clearance from the U.S. FDA for Echogo Amyloidosis, its artificial intelligence-enhanced software that helps with the early diagnosis of cardiac amyloidosis, enabling timely ...
Patients with sarcoidosis using ACE inhibitors vs ARBs had greater risk for 5-year mortality, sepsis, respiratory failure, AMI, and cerebral infarction. Patients with sarcoidosis treated with ...
The severe cardiac events are often fatal, and while Abrunzo's father survived, it inspired him to take his heart health seriously, since family history is one of the strongest indicators for ...
Cardiac amyloidosis is a rare condition defined by the abnormal production of proteins that bind together to form amyloid proteins. These amyloids can gather in different organs throughout the ...
A cardiac electrophysiologist is a cardiologist who has 2 years of extra training to learn about heart rhythms and how to diagnose problems with them. Training to become certified as a cardiac ...
In patients with out-of-hospital cardiac arrest, the effectiveness of drugs such as epinephrine is highly time-dependent. An intraosseous route of drug administration may enable more rapid drug ...
Early data suggest Roche’s antibody may safely and quickly remove amyloid plaque for patients with Alzheimer’s disease, though the midstage study has been tied to one death. The interim data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback